Online inquiry

IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14927MR)

This product GTTS-WQ14927MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets stx2 A-subunit gene. The antibody can be applied in hemolytic-uremic syndrome (HUS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq WP_001367518.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID Q8VLD2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14927MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2631MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ5292MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ15780MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ12846MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ13190MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ7068MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ11475MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ12606MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW